RomiCar: Phase I/II study to determine the maximum tolerated dose and activity of the combination of romidepsin and carfilzomib in relapsed or refractory peripheral T-cell lymphoma

Trial Overview and Summary

Peripheral T cell lymphoma (PTCL) is a type of high grade (quickly growing) non Hodgkin lymphoma (NHL) that affects blood cells called T cells.

Doctors often use chemotherapy to treat PTCL. But sometimes it continues to grow, or comes back after the treatment has finished. So doctors are looking for new ways to treat people in this situation.

This trial is looking at 2 drugs called romidepsin and carfilzomib. The researchers want to see if romidepsin and carfilzomib help people who have already had other treatment for PTCL.

Please note that the trials team cannot give individual’s clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible

Chief Investigator:  Dr Graham Collins
Sponsor:  University of Birmingham
Funders:  TAP Bloodwise
Disease Site:  Peripheral T cell lymphoma
Trial Type:  Clinical Trial of an Investigational Medicinal Product
Status:  Open
UKCRN Study ID: (if applicable)  15553
Open to new sites?  Yes
Recruitment start date:  13-Jul-2015
Anticipated Recruitment end date  12-Jul-2018
CRCTU Trial Management Team:  Haematology Team
Trial E-mail Address:

Trial Protocol

Please Note:

Clinical trial protocols are complex technical documents which should only be used for the treatment of subjects taking part in the trial. Patients who are interested in taking part in the trial are advised to talk to their health care professional or refer to CancerHelp website.

Investigators please ensure you have R&D approval for this specific version of the protocol before using as a reference.

More Information

Please Note:

CancerHelp (Cancer Research UK) - RomiCar trial